Muttenz, October 31, 2019 - Clariant, a focused and innovative specialty chemical company, today announced the completion of the sale of its Healthcare Packaging business to a newly-formed investment of Arsenal Capital Partners, the signing of which was announced on July 22, 2019. The sale was closed on October 31, 2019.
"The divestment of the Healthcare Packaging business is the first step of our announced strategy to become a more focused and innovative specialty chemical company," said Hariolf Kottmann, Executive Chairman of Clariant.
The total consideration of the sale amounts to approximately CHF 308 million which is equivalent to 13.2 times adjusted FY 2018 EBITDA.
| CORPORATE MEDIA RELATIONS | INVESTOR RELATIONS |
| Jochen Dubiel Phone +41 61 469 63 63 jochen.dubiel@clariant.com | Maria Ivek Phone +41 61 469 63 73 maria.ivek@clariant.com |
| Claudia Kamensky Phone +41 61 469 63 63 claudia.kamensky@clariant.com | Alexander Kamb Phone +41 61 469 63 73 alexander.kamb@clariant.com |
| Thijs Bouwens Phone +41 61 469 63 63 Thijs.bouwens@clariant.com | |
Follow us on Twitter (https://twitter.com/clariant), Facebook (https://www.facebook.com/pages/Clariant/146077545551792), LinkedIn (https://www.linkedin.com/company/clariant), Instagram (https://www.instagram.com/clariant_international/). | |
| This media release contains certain statements that are neither reported financial results nor other historical information. This document also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company's ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials. www.clariant.com (http://www.clariant.com) Clariant is a focused and innovative specialty chemical company, based in Muttenz near Basel/Switzerland. On 31 December 2018 the company employed a total workforce of 17 901. In the financial year 2018, Clariant recorded sales of CHF 4.404 billion for its continuing businesses. The company reports in three business areas: Care Chemicals, Catalysis and Natural Resources. Clariant's corporate strategy is based on five pillars: focus on innovation and R&D, add value with sustainability, reposition portfolio, intensify growth, and increase profitability. | |
Attachment
- ClariantCompletesSale_Healthcare Packaging_20191031_EN (https://ml-eu.globenewswire.com/Resource/Download/f5fd8afc-a75d-426c-bbe8-1f1e3d170ed5)
© 2019 GlobeNewswire (Europe)
